» Articles » PMID: 17051362

[Juvenile Dermatomyositis]

Overview
Journal Z Rheumatol
Publisher Springer
Specialty Rheumatology
Date 2006 Oct 20
PMID 17051362
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Juvenile dermatomyositis (JDM) is an inflammatory multi-system disease of unknown etiology with classic involvement of the skin and striated muscles. Following a prodromal period, patients develop a progressive proximal muscle weakness. Typical skin involvement includes heliotrope rash, facial erythema, Gottron's sign and nailfold capillary abnormalities. For the diagnosis of JDM, modified Bohan and Peter criteria are used including clinical skin and muscle signs plus elevated muscle enzymes and typical findings from electromyography, muscle biopsy and - more recently - also on magnetic resonance imaging. Steroids are administered classically as high-dose oral treatment. Intravenous pulse therapy with intermittent lower dose oral treatment and other immunosuppressive drugs such as methotrexate may reduce steroid side-effects. Prognosis in JDM has improved, and most patients eventually make a full functional recovery. However, a few patients still die from their disease, and in a minority significant sequelae with muscle atrophy or severe calcinosis ensue.

Citing Articles

[Dermatomyositis and juvenile dermatomyositis].

Dressler F, Maurer B Z Rheumatol. 2022; 82(3):233-245.

PMID: 35486206 DOI: 10.1007/s00393-022-01205-5.


[Juvenile dermatomyositis-what's new?].

Hinze C Z Rheumatol. 2019; 78(7):627-635.

PMID: 31087132 DOI: 10.1007/s00393-019-0643-6.


Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria.

Hinze C, Oommen P, Dressler F, Urban A, Weller-Heinemann F, Speth F Pediatr Rheumatol Online J. 2018; 16(1):40.

PMID: 29940960 PMC: 6019723. DOI: 10.1186/s12969-018-0257-6.


Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists.

Hinze C, Speth F, Oommen P, Haas J Pediatr Rheumatol Online J. 2018; 16(1):38.

PMID: 29925381 PMC: 6011340. DOI: 10.1186/s12969-018-0256-7.


Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.

Speth F, Haas J, Hinze C Pediatr Rheumatol Online J. 2016; 14(1):52.

PMID: 27623619 PMC: 5022227. DOI: 10.1186/s12969-016-0112-6.

References
1.
Crowe W, Bove K, LEVINSON J, Hilton P . Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum. 1982; 25(2):126-39. DOI: 10.1002/art.1780250203. View

2.
Verma S, Singh S, Bhalla A, Khullar M . Study of subcutaneous fat in children with juvenile dermatomyositis. Arthritis Rheum. 2006; 55(4):564-8. DOI: 10.1002/art.22108. View

3.
Symmons D, Sills J, Davis S . The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995; 34(8):732-6. DOI: 10.1093/rheumatology/34.8.732. View

4.
Wargula J, Lovell D, Passo M, Bove K, Santangelo J, LEVINSON J . What more can we learn from muscle histopathology in children with dermatomyositis/polymyositis?. Clin Exp Rheumatol. 2006; 24(3):333-43. View

5.
McCann L, Juggins A, Maillard S, Wedderburn L, Davidson J, Murray K . The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006; 45(10):1255-60. DOI: 10.1093/rheumatology/kel099. View